Freshfields Bruckhaus Deringer, Gibson, Dunn & Crutcher, King & Wood Mallesons and DLA Piper have advised Chinese biopharma company Hutchmed on its HK$4.17 billion ($537 million) secondary listing in Hong Kong.
Linklaters, Davis Polk & Wardwell and JunHe are counselling the joint sponsors and underwriters, namely Morgan Stanley Asia, Jefferies Hong Kong and China International Capital Corporation.
Listed on the AIM market of the London Stock Exchange since 2006, Hutchmed also has American Depositary Shares (ADSs) listed on the Nasdaq Global Select Market. It is a biopharmaceutical company focused on the discovery, development and commercialisation of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases.
Partners Kevin Cheung and Christopher Yip led the Linklaters team. Conyers is providing offshore legal advice to the issuer.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.